Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Patent
1997-10-23
2000-09-05
Clardy, S. Mark
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
424422, 424434, 424435, 514262, 514274, A61F 1300
Patent
active
061139203
ABSTRACT:
A pharmaceutical composition and a method of inhibiting human immunodeficiency virus (HIV) is disclosed which comprises administering to an HIV infected patient a homogenous combination of lamivudine, zidovudine and a pharmaceutical glidant in an amount which achieves antiviral efficacy.
REFERENCES:
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5859021 (1999-01-01), Cameron et al.
Ford, Katherine, et. al, "Investigations Leading To The Elimination of Segregation in a Direct Compression Combination Product," Pharmaceutical Research, Sep. 1996 (Supplement), vol. 13, No. 9, p. S206 (PT 6198).
Hammer, Scott M., "Advances in antiretroviral therapy and viral load monitoring," One world. One hope, XI International Conference on AIDS, 1996 vol. 10 (suppl 3):S1-S11.
St. Clair, M.H., et. al., "In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents," Antiviral Research 29 (1996) 53-56.
Tisdale, Margaret, et. al., "Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'--thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase," Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5653-5656. Jun. 1993 Medical Sciences.
Glaxo Wellcome Retrovir.RTM. (zidovudine) Tablets, Capsules and Syrup Product Information Package Insert, Glaxo Wellcome Inc., Research Triangle Park, NC 27709, Sep. 1996.
Glaxo Wellcome Epivir.RTM. Tablets Solution (lamivudine tablets) and Epivir.RTM. Oral (lamivudine oral solution) Product Information Package Insert, Glaxo Wellcome Inc., Research Triangle Park, NC 27709 Aug. 1996.
Rudnic, et. al., "Oral Solid Dosage Forms," Remington: The Science and Practice of Pharmacy, vol. II, Chapter 92, pp. 1615-1649.
Editor: Walter Lund, "Oral Solids,"The Pharmaceutical Codex, Twelfth Edition, Principles and Practice of Pharmaceutics, 1994, pp. 2-30, The Pharmaceutical Press, London, 1994.
Glaxo Group Limited et al., PCT International Preliminary Examination Report for PCT/EP97/05953, completed Jan. 25, 1999.
Goodson Gary Wayne
Maye Katherine Jeannette
Wood Allen Wayne
Clardy S. Mark
Dadswell Charles E.
Glaxo Wellcome Inc.
Prus Karen L.
Shelborne Kathryne E.
LandOfFree
Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2209343